… Erlotinib was prescribed more frequently than gefitinib in … EGFR, the effectiveness of gefitinib
and erlotinib, including drug … drug selection between erlotinib and gefitinib in clinical practice…

… Gefitinib, erlotinib and afatinib are three widely used … ) for treating advanced non-small cell
lung cancer (NSCLC) with proven … Gefitinib and erlotinib demonstrated comparable effects on …

… that the accumulated evidence with erlotinib and gefitinib indicates gefitinib's activity and
safety as a cancer therapeutic for patients with NSCLC is at least as good as that of erlotinib. …

… receive erlotinib (150 mg per day) or gefitinib (250 mg per day) orally until disease progression
or unacceptable toxicity. We aimed to determine whether erlotinib is superior to gefitinib …

… , gefitinib and erlotinib, have changed the treatment paradigm of advanced non-small … lung
cancer (NSCLC). Many phase II or III studies have proven the efficacy of gefitinib or erlotinib …

… of erlotinib are higher than those of gefitinib, which supports the view that patients can achieve
longer PFS with erlotinib treatment than with gefitinib and that erlotinib can … , than gefitinib. …

… identified in a patient with advanced lung cancer who progressed on erlotinib maintenance
therapy, and subsequently had leptomeningeal metastases that responded to gefitinib [33]. …

… associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor. In-…
gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib…

… for use of erlotinib, as for gefitinib. By comparison with PFS for gefitinib (10.4 months in
NEJ002 and 9.2 months in WJTOG), a median PFS of 13.1 months with erlotinib in OPTIMAL is …

… our lung cancer patients to compare the benefits derived from erlotinib and gefitinib and to
… We subsequently analyzed tumor tissue from a subgroup of these patients for a pilot study to …